Impact of statin on long-term outcome among patients with end-stage renal disease with acute myocardial infarction (AMI): a nationwide case–control study. Issue 1147 (15th January 2021)

• Record Type: Journal Article
• Authors: Kuo, Feng-You; Huang, Wei-Chun; Tang, Pei-Ling; Cheng, Chin-Chang; Chiang, Cheng-Hung; Lin, Hsiao-Chin; Chuang, Tzu-Jung; Wann, Shue-Ren; Mar, Guang-Yuan; Liu, Chun-Peng; Cheng, Juei-Tang; Wu, Ming-Chang
• Is Part Of: Postgraduate medical journal. Volume 97:Issue 1147(2021)
• Page Start: 299
• Page End: 305
• Publication Date: 2021-01-15
• Subjects: nephrology -- clinical audit; Medicine -- Periodicals; 610
• DOI: 10.1136/postgradmedj-2019-137292
• Languages: English
• ISSNs: 0032-5473

Abstract

ABSTRACT: Background: Use of statin has been associated with reduced risk of cardiovascular diseases events and mortality. However, in patients with end-stage renal disease (ESRD), the protective effects of statin are controversial. To evaluate the impact of chronic statin use on clinical outcomes of patients with acute myocardial infarction (AMI) with ESRD. Methods: We enrolled 8056 patients with ESRD who were initially diagnosed and admitted for first AMI from Taiwan's National Health Insurance Research Database. Of which, 2134 patients underwent statin therapy. We randomly selected and use age, sex, hypertension, diabetes mellitus (DM), peripheral vascular diseases (PVD), heart failure (HF), cerebrovascular accidents (CVA), chronic obstructive pulmonary disease, matched with the study group as controls (non-stain user). We compared the effects of statin use in term of all-cause death among patients with AMI with ESRD. Results: Statin use resulted in a significantly higher survival rate in patients ith AMI with ESRD compared with non-statin users. After adjusted the comorbidities the male patients and patients with DM, PVD, HF and CVA had lower long-term survival rate (all p<0.001). Patients who underwent percutaneous coronary intervention (p<0.001), ACE inhibitors/angiotensin II receptor blockers (p<0.001), β receptor blockers (p<0.001) and statin therapy (p=0.007) had better long-term survival rate. Patients with AMI with ESRD on statin therapy exhibited a significantly lower risk of mortality compared with non-statin users (p<0.0001). Conclusion: Among patients with ESRD with AMI, statin therapy was associated with reduced all-cause mortality.